Literature DB >> 7669644

Malignancy-associated multicentric reticulohistiocytosis: a clinical, histological and immunophenotypic study.

J L Snow1, S A Muller.   

Abstract

The clinical, histopathological, and immunophenotypic characteristics of four cases of malignancy-associated multicentric reticulohistiocytosis (MMR) and one case each of diffuse cutaneous reticulohistiocytosis (DCR) and isolated reticulohistiocytoma (IR), are reviewed. In all four cases of MMR the cutaneous lesions and joint manifestations were judged to be concurrent with the diagnosis of malignancy. Malignancies observed included one case each of pancreatic adenocarcinoma, squamous cell carcinoma of the lung, metastatic melanoma and intraperitoneal grade 4 mucinous adenocarcinoma of uncertain origin. Histologically, all six cases demonstrated the typical changes of a diffuse histiocytic and multinucleated giant cell infiltrate with ground-glass cytoplasm, predominantly in the upper dermis. Immunohistochemical investigation revealed strong cytoplasmic staining with KP-1 (CD68) in all six cases. Prominent membrane staining was noted with leucocyte common antigen (CD45) in four cases (three MMR and one IR), and CD3 in four cases (three MMR and one IR). Weak membrane staining with Leu 22 (CD43) was noted in two MMR cases. UCHL-1 (CD45RO), L26 (CD20), S-100 and BerH2 stains were all uniformly negative. A prominent number of perilesional factor XIIIa-positive dermal dendrocytes were noted in the single case of IR, in contrast with the other five cases. We conclude that MMR, DCR and IR are histopathologically and immunohistochemically similar. The pattern of immunoreactivity observed is consistent with a monocyte-macrophage origin of the infiltrating tumour cells. We emphasize the paraneoplastic association of multicentric reticulohistiocytosis, which we have observed in four of 13 such cases (31%) evaluated at our institution.

Entities:  

Mesh:

Year:  1995        PMID: 7669644     DOI: 10.1111/j.1365-2133.1995.tb02495.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

Review 1.  Multicentric reticulohistiocytosis: a rare yet challenging disease.

Authors:  Arshia D Islam; Stanley M Naguwa; Gurtej S Cheema; John C Hunter; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

2.  Malignancy-associated multicentric reticulohistiocytosis.

Authors:  Boutros El-Haddad; Dalia Hammoud; Timothy Shaver; Shadi Shahouri
Journal:  Rheumatol Int       Date:  2009-12-12       Impact factor: 2.631

3.  Rheumatic diseases and malignancies.

Authors:  Violeta Bojinca; Iustina Janta
Journal:  Maedica (Buchar)       Date:  2012-12

4.  Multiple cutaneous reticulohistiocytomas successfully treated with topical psoralen plus ultraviolet A therapy combined with intralesional injections of triamcinolone acetonide.

Authors:  Adam G Harris; Asri Wijayanti; Marcia Llewellyn; Jihan Muhaidat; Steven Kossard; Dedee F Murrell
Journal:  JAAD Case Rep       Date:  2015-05-25

5.  Multicentric reticulohistiocytosis in a patient with thymic carcinoma.

Authors:  Samantha Shwe; Aditi Sharma; Ashley N Elsensohn; Linda Doan; Janellen Smith
Journal:  JAAD Case Rep       Date:  2019-08-05

6.  Multicentric reticulohistiocytosis presenting with papulonodular skin lesions and arthritis mutilans.

Authors:  Raya Saba; Shawn G Kwatra; Bishwas Upadhyay; Aibek E Mirrakhimov; Farah N Khan
Journal:  Case Rep Rheumatol       Date:  2013-03-10

7.  Multicentric reticulohistiocytosis associated with liver carcinoma: report of a case.

Authors:  Ling Han; Qiong Huang; Kang-Huang Liao; Lian-Jun Chen; Wen-Yi Kong; Wen-Wen Fu; Jing-Hua Xu
Journal:  Case Rep Dermatol       Date:  2012-08-01

8.  Multiple Cutaneous Reticulohistiocytoma.

Authors:  Karishma D Hemmady; Shylaja S Someshwar; Hemangi R Jerajani
Journal:  Indian J Dermatol       Date:  2016 Jan-Feb       Impact factor: 1.494

9.  Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis.

Authors:  Daniel J Zinn; Olive Eckstein; Mary L Olsen; Carl E Allen; Kenneth L McClain
Journal:  Dermatol Case Rep       Date:  2019-04-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.